Skip to content
Blerp – Lifestyle
Author:
Arcutis Biotherapeutics, Inc.
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
April 27, 2026
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
April 22, 2026
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
April 15, 2026
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
March 31, 2026
←
Previous Page
1
2
3